Company profile: Tris Pharma
1.1 - Company Overview
Company description
- Provider of specialty generic pharmaceuticals leveraging its LiquiXR drug delivery technology for sustained-release formulations, including ADHD treatments with flexible dosing for patients aged 6+, a portfolio of 10 generic products with 20+ in development, technology licensing of its delivery technologies, and partnerships to enhance product development and commercialization.
Products and services
- ADHD Products: LiquiXR-enabled therapies offering flexible dosing for patients aged 6 and older, providing sustained-release treatment options for ADHD
- LiquiXR Drug Delivery Technology: Proprietary, sustained-release platform suitable for various formulations, including those aiding patients with ADHD, enabling sustained release of medication
- Generics Portfolio: Specialty-focused, high-quality generics comprising 10 products with over 20 in development, offered as patient-friendly options
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Tris Pharma
Atalanta Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology focused on pioneering new treatment options for neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Atalanta Therapeutics company profile →
ANS Medical
HQ: United States
Website
- Description: Provider of neuromodulation devices, engaged in their design, development, and manufacture.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ANS Medical company profile →
CNS Therapeutics
HQ: United States
Website
- Description: Provider of pharmaceuticals for site-specific delivery to the central nervous system to treat neurological disorders and chronic pain; develops and markets safe, high-quality pharmaceuticals, including its first FDA-approved product, Gablofen. Based in St. Paul, Minn.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CNS Therapeutics company profile →
BlackThorn Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage neurobehavioral health, pioneering the next generation of artificial intelligence.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BlackThorn Therapeutics company profile →
Inscopix
HQ: United States
Website
- Description: Provider of neural activity imaging solutions for freely behaving subjects, enabling links between circuit dynamics and behavior. Offers the nVue dual-color system with expanded storage for longitudinal studies, the LScape module for wider field of view and longer working distance in cortical imaging, and Multicolor Data Processing software for streamlined miniscope analysis with PCA/ICA or CNMFe, filtering, and longitudinal registration.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Inscopix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Tris Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Tris Pharma
2.2 - Growth funds investing in similar companies to Tris Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Tris Pharma
4.2 - Public trading comparable groups for Tris Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →